Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmra2034861
10.1056/nejmra2034861 · External reference
Unresolved reference
External reference
10.1056/nejmoa1104621
10.1056/nejmoa1104621 · External reference
10.1056/nejmoa1412082
10.1056/nejmoa1412082 · External reference
10.1056/nejmoa1503093
10.1056/nejmoa1503093 · External reference
10.1056/nejmoa1709684
10.1056/nejmoa1709684 · External reference
10.1056/nejmoa1103782
10.1056/nejmoa1103782 · External reference
10.1056/nejmoa1412690
10.1056/nejmoa1412690 · External reference
10.1016/s1470-2045(16)30122-x
10.1016/s1470-2045(16)30122-x · External reference
10.1093/annonc/mdx176
10.1093/annonc/mdx176 · External reference
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(18)30497-2 · 2018 · External reference
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
10.1001/jamainternmed.2018.8351 · 2019 · External reference
10.1016/s1470-2045(14)70007-5
10.1016/s1470-2045(14)70007-5 · External reference
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
10.1097/md.0000000000003997 · 2016 · External reference
10.1158/1078-0432.ccr-17-1902
10.1158/1078-0432.ccr-17-1902 · External reference
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis
10.1001/jamaoncol.2017.5236 · 2018 · External reference
A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes
10.1001/jamanetworkopen.2018.0416 · 2018 · External reference
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
10.1007/s00432-018-2738-x · 2018 · External reference
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
10.1186/s40425-019-0513-4 · 2019 · External reference
Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis
10.1001/jamanetworkopen.2020.11809 · 2020 · External reference
Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
10.1177/1758835920929583 · 2020 · External reference
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma
2021 · External reference
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
10.3390/cancers14071804 · 2022 · External reference
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial
10.1016/j.esmoop.2021.100340 · 2022 · External reference
CO153 Predicting Overall Survival (OS) Benefit in Previously Untreated Metastatic Melanoma From Improvements in Response Outcomes: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
10.1016/j.jval.2024.03.240 · 2024 · External reference
Predicting overall survival benefit in previously untreated, unresectable or metastatic melanoma from improvement in progression-free survival: a correlation meta-analysis
10.3389/fonc.2025.1541086 · 2025 · External reference
CO29 An Ensemble Approach to Predicting Overall Survival (OS) Benefit Jointly From Multiple Surrogate Endpoints (SE) in Oncology: A Case Study in Previously Untreated Metastatic Melanoma
10.1016/j.jval.2024.10.106 · 2024 · External reference
10.1007/b138566
10.1007/b138566 · External reference
10.1093/oncolo/oyac006
10.1093/oncolo/oyac006 · External reference
10.1056/nejmoa1504030
10.1056/nejmoa1504030 · External reference
10.1056/nejmoa1414428
10.1056/nejmoa1414428 · External reference
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
10.1200/jco.18.01998 · 2019 · External reference
10.1016/j.ejca.2008.10.026
10.1016/j.ejca.2008.10.026 · External reference
10.1016/s1470-2045(16)30366-7
10.1016/s1470-2045(16)30366-7 · External reference
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF -mutant melanoma
10.1136/jitc-2020-001806 · 2020 · External reference
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
10.1016/j.ejca.2018.06.034 · 2018 · External reference
10.1158/1078-0432.ccr-21-0793
10.1158/1078-0432.ccr-21-0793 · External reference
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
10.1200/jco.24.01124 · 2025 · External reference
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(20)30934-x · 2020 · External reference
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
10.1016/j.annonc.2020.12.004 · 2021 · External reference
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
10.1200/jco.23.00172 · 2023 · External reference
1102P Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
10.1016/j.annonc.2023.09.2236 · 2023 · External reference
10.1200/jco.2014.56.5887
10.1200/jco.2014.56.5887 · External reference
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
10.1016/s0140-6736(00)02528-9 · 2000 · External reference
10.1200/jco.2007.11.8836
10.1200/jco.2007.11.8836 · External reference
10.1200/jco.2007.10.8407
10.1200/jco.2007.10.8407 · External reference
10.1093/jnci/djt269
10.1093/jnci/djt269 · External reference
10.1093/jnci/djt270
10.1093/jnci/djt270 · External reference
10.1093/jnci/djx133
10.1093/jnci/djx133 · External reference
10.1016/s1470-2045(18)30750-2
10.1016/s1470-2045(18)30750-2 · External reference
10.1200/jco.22.02363
10.1200/jco.22.02363 · External reference
10.1056/nejmoa2407417
10.1056/nejmoa2407417 · External reference
10.1056/nejmoa1507643
10.1056/nejmoa1507643 · External reference
10.1016/s0140-6736(15)01281-7
10.1016/s0140-6736(15)01281-7 · External reference
10.1056/nejmoa1602252
10.1056/nejmoa1602252 · External reference
10.1056/nejmoa1510665
10.1056/nejmoa1510665 · External reference
10.1056/nejmoa1613683
10.1056/nejmoa1613683 · External reference
10.1016/s1470-2045(19)30274-8
10.1016/s1470-2045(19)30274-8 · External reference
10.1200/jco.22.00343
10.1200/jco.22.00343 · External reference
10.1001/jama.2024.2396
10.1001/jama.2024.2396 · External reference
10.1200/jco.22.00535
10.1200/jco.22.00535 · External reference
